[Long-term treatment with Des-Phe-Insulin]. 1982

S Hirn, and H Pietschmann

At a geriatric department 61 insulin-dependent diabetics have been treated with des-phe-insulin (DPI) for periods of up to 6 years since 1976. The use of either pure DPI, amorphous DPI or DPI mixed with varying amounts of crystalline non-modified insulin of the same species allowed flexible longterm therapy, as well as management of metabolic emergencies. Comparison of the doses needed before and after change to and from other insulin preparations showed no difference in efficacy. No side effects of such severity as to necessitate interruption of therapy were observed.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013453 Sulfonylurea Compounds A class of compounds in which a sulfone functional group is attached to UREA. Compounds, Sulfonylurea
D016883 Diabetic Ketoacidosis A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA. Acidosis, Diabetic,DKA Diabetic Ketoacidosis,Diabetic Acidosis,Diabetic Ketosis,Ketoacidosis, Diabetic,Ketosis, Diabetic,Acidoses, Diabetic,DKA Diabetic Ketoacidoses,Diabetic Acidoses,Diabetic Ketoacidoses,Diabetic Ketoacidosis, DKA,Diabetic Ketoses,Ketoacidoses, Diabetic,Ketoacidosis, DKA Diabetic,Ketoses, Diabetic

Related Publications

S Hirn, and H Pietschmann
November 1979, Deutsche medizinische Wochenschrift (1946),
S Hirn, and H Pietschmann
July 1979, Deutsche medizinische Wochenschrift (1946),
S Hirn, and H Pietschmann
March 1982, Deutsche medizinische Wochenschrift (1946),
S Hirn, and H Pietschmann
July 1979, Archives of gynecology,
S Hirn, and H Pietschmann
January 1976, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
S Hirn, and H Pietschmann
October 1983, Ugeskrift for laeger,
Copied contents to your clipboard!